Biogen (BIIB) vs ImmunityBio (IBRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ImmunityBio (IBRX) has outperformed Biogen (BIIB) over the past year, gaining 290.0% versus a gain of 45.9%. Over five years, IBRX leads with a +4.8% price change compared with -21.0% for BIIB. Biogen is the larger company by market cap ($32.82 billion vs $10.33 billion), about 3.2 times the size, while ImmunityBio is growing revenue faster (+668.3% vs +2.2%).
Biogen converts more of its revenue into profit, with a net margin of 13.1% versus -310.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIIB | IBRX |
|---|---|---|
| Share price | $222.15 | $9.75 |
| Market cap | $32.82B | $10.33B |
| 1-day change | -0.33% | +0.62% |
| YTD return | +26.23% | +392.42% |
| 1-year return | +45.95% | +290.00% |
| 5-year return | -21.00% | +4.84% |
| P/E ratio (TTM) | 39.46 | — |
| Forward P/E | 13.43 | — |
| EPS (TTM) | $5.63 | $-0.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $9.89B | $113.29M |
| Revenue growth (YoY) | +2.22% | +668.31% |
| Net income (latest FY) | $1.29B | $-351.40M |
| Gross margin | 75.69% | 99.34% |
| Operating margin | — | -226.00% |
| Net margin | 13.07% | -310.18% |
| 52-week high | $230.49 | $12.43 |
| 52-week low | $138.00 | $1.95 |
| Distance from 52-week high | -3.62% | -21.56% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +7.22% | +30.77% |
| Average volume | 1.06M | 10.27M |
| Shares outstanding | 147.75M | 1.06B |
| Employees | 7,500 | 684 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Biogen is about 3.2 times larger than ImmunityBio by market value ($32.82B vs $10.33B).
- IBRX has outperformed BIIB by 244.1 percentage points over the past year.
- Biogen is more profitable, keeping 13.1 cents of every revenue dollar as net income versus -310.2 cents for ImmunityBio.
- ImmunityBio grew revenue faster in its latest fiscal year (+668.31% vs +2.22%).
About Biogen
BIIB stock →Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,500 employees
About ImmunityBio
IBRX stock →ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 684 employees
BIIB vs IBRX FAQ
Which is bigger, Biogen or ImmunityBio?
Biogen (BIIB) is larger, with a market capitalization of $32.82B compared with $10.33B for ImmunityBio (IBRX).
Which stock has performed better over the past year, BIIB or IBRX?
IBRX returned +290.00% over the past 12 months, compared with +45.95% for BIIB (price return, excluding dividends). Past performance does not predict future results.
Are Biogen and ImmunityBio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.